Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
Addiction2013Vol. 108(12), pp. 2141–2149
Citations Over TimeTop 10% of 2013 papers
Richard N. Rosenthal, Walter Ling, Paul Casadonte, Frank J. Vocci, Genie L. Bailey, Kyle M. Kampman, Ashwin A. Patkar, Steven Chavoustie, Christine Blasey, Stacey C. Sigmon, Katherine Beebe
Abstract
Compared with placebo, buprenorphine implants result in significantly less frequent opioid use and are non-inferior to sublingual buprenorphine/naloxone tablets.
Related Papers
- → The Next Stage of Buprenorphine Care for Opioid Use Disorder(2018)133 cited
- → Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment(2022)2 cited
- → Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments(2023)1 cited
- → Can buprenorphine be used for opioid use disorder during pregnancy?(2021)
- → Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment (Preprint)(2022)